Great Point Partners, Llc
- Regulatory AUM
- $1.8B
- Discretionary
- $1.8B
- Clients
- 17
- Avg AUM / client
- $105M
- Accounts
- 17
- Employees
- 28
AUM over time
Reported AUM from Form ADV filings, plotted by filing date · as of Mar 31, 2026
Investments (13F portfolio — 42 positions, $435,118,234)
13F period Mar 31, 2026| # | Issuer | Class | Value | Shares | % of 13F | % of AUM |
|---|---|---|---|---|---|---|
| 1 | Apogee Therapeutics Inc | COM | $31,479,580 | 374,000 | 7.23% | 1.77% |
| 2 | Vor Biopharma Inc | COM NEW | $31,220,000 | 1,750,000 | 7.18% | 1.76% |
| 3 | Zura Bio Ltd | CLASS A ORD SHS | $25,084,784 | 4,215,930 | 5.77% | 1.41% |
| 4 | Amylyx Pharmaceuticals Inc | COM | $24,325,000 | 1,750,000 | 5.59% | 1.37% |
| 5 | Immunitybio Inc | COM | $23,016,136 | 3,000,800 | 5.29% | 1.3% |
| 6 | Nektar Therapeutics | COM NEW | $22,768,793 | 316,453 | 5.23% | 1.28% |
| 7 | Sol Gel Technologies Ltd | SHS NEW | $21,735,037 | 274,363 | 5.0% | 1.22% |
| 8 | Alumis Inc | COM | $18,859,024 | 856,061 | 4.33% | 1.06% |
| 9 | Bright Minds Biosciences Inc | COM NEW | $16,053,400 | 220,000 | 3.69% | 0.9% |
| 10 | Annexon Inc | COM | $13,850,000 | 2,500,000 | 3.18% | 0.78% |
| 11 | Kalvista Pharmaceuticals Inc | COM | $13,587,750 | 675,000 | 3.12% | 0.76% |
| 12 | Immunovant Inc | COM | $13,553,325 | 545,625 | 3.11% | 0.76% |
| 13 | Jade Biosciences Inc | COM NEW | $13,550,691 | 964,462 | 3.11% | 0.76% |
| 14 | Contineum Therapeutics Inc | CL A | $10,450,586 | 800,198 | 2.4% | 0.59% |
| 15 | Zenas Biopharma Inc | COM | $10,245,490 | 524,066 | 2.35% | 0.58% |
| 16 | Neurogene Inc | COM | $10,080,000 | 500,000 | 2.32% | 0.57% |
| 17 | Moonlake Immunotherapeutics | CLASS A ORD | $9,320,000 | 500,000 | 2.14% | 0.52% |
| 18 | Climb Bio Inc | COM | $9,138,791 | 1,334,130 | 2.1% | 0.51% |
| 19 | Oruka Therapeutics Inc | COM | $8,992,337 | 183,330 | 2.07% | 0.51% |
| 20 | Eupraxia Pharmaceuticals Inc | COM | $8,688,000 | 1,200,000 | 2.0% | 0.49% |
| 21 | Vera Therapeutics Inc | CL A | $8,019,770 | 199,348 | 1.84% | 0.45% |
| 22 | Evommune Inc | COM SHS | $7,471,750 | 325,000 | 1.72% | 0.42% |
| 23 | Lb Pharmaceuticals Inc | COM SHS | $7,398,000 | 300,000 | 1.7% | 0.42% |
| 24 | Compass Therapeutics Inc | COM | $7,141,500 | 1,350,000 | 1.64% | 0.4% |
| 25 | Scynexis Inc | COM NEW | $6,926,581 | 7,554,347 | 1.59% | 0.39% |
Top 25 of 42 positions from the manager's latest Form 13F · source filing (EDGAR) ↗. 13F covers long US-listed positions only. "% of AUM" is share of the firm's total regulatory AUM (Form ADV Item 5.F).
Who they serve
| Client type | Clients | AUM | % of AUM |
|---|---|---|---|
| Pooled investment vehicles (non-investment companies) | 17 | $1.8B | 100.0% |
Private funds (20)
View all →Reported in Form ADV Section 7.B.(1), filing of Oct 2024 · $1.9B combined gross assets
| Fund | Type | Domicile | Gross assets | Owners |
|---|---|---|---|---|
| Great Point Partners Iv, L.P. | Private Equity Fund | Delaware | $535M | 145 |
| Biomedical Value Fund, L.P. | Hedge Fund | Delaware | $516M | 94 |
| Biomedical Offshore Value Fund, Ltd. | Hedge Fund | Cayman Islands | $336M | 83 |
| Great Point Partners Iii, Lp | Private Equity Fund | Delaware | $291M | 109 |
| Great Point Partners Ii, Lp master | Private Equity Fund | Delaware | $65.8M | 103 |
| Great Point Partners Iii A, L.P. | Private Equity Fund | Delaware | $51.3M | 24 |
| Gpp Iii Pcm, Llc | Private Equity Fund | Delaware | $31.3M | 32 |
| Gpp Cf I, Lp | Private Equity Fund | Delaware | $29.6M | 62 |
| Gpp Iii Ephicacy, Llc | Private Equity Fund | Delaware | $20.8M | 25 |
| Great Point Partners Ii A, Lp | Private Equity Fund | Delaware | $20.1M | 16 |
| Gpp Iii Axiom, Llc | Private Equity Fund | Delaware | $14.7M | 22 |
| Gpp Iii Mlm, Llc | Private Equity Fund | Delaware | $5.3M | 24 |
| Gpp Iv Ludi, Llc | Private Equity Fund | Delaware | $2.7M | 13 |
| Gpp Ii Salmon Co Invest, L.P. | Private Equity Fund | Cayman Islands | $2.2M | 19 |
| Gpp Ii Ucs, Llc | Private Equity Fund | Delaware | $2.2M | 19 |
People (4)
| Name | Role / title | Credentials | With firm since | Ownership |
|---|---|---|---|---|
| Jay, Jeffrey, Robert | Elected Manager, Member And Managing Director | Jan 2003 (24y) | 50% – 75% | |
| Penn, Kevin | Trustee | Oct 2003 (23y) | GP / trustee / elected manager of The Jay Family Spray Trust (indirect) | |
| Panzier, Ronald, Marc | Chief Operating Officer And Chief Financial Officer | Jul 2010 (16y) | Less than 5% | |
| Felsenthal, Adam, Brian | General Counsel And Chief Compliance Officer | Dec 2023 (3y) | Less than 5% |
Entity owners (Schedule A/B)
| Entity | Title / status | Since | Sch. | Ownership |
|---|---|---|---|---|
| The Jay Family Spray Trust | Associated Non Managing Member | Oct 2003 | A | 25% – 50% |
Undisclosed: 0% – 25% of the firm is not attributable from the filed Schedule A bands.
Roster from the IAPD representatives feed; ownership and acquisition dates from Form ADV Schedule A/B. "Since" is the earliest filed registration or acquisition date.
Private funds (20, $1.9B gross assets)
| Fund | Type | Gross assets | Min. investment | Owners |
|---|---|---|---|---|
| Great Point Partners Iv, L.P. | Private Equity Fund | $535M | $1.0M | 145 |
| Biomedical Value Fund, L.P. | Hedge Fund | $516M | $1.0M | 94 |
| Biomedical Offshore Value Fund, Ltd. | Hedge Fund | $336M | $1.0M | 83 |
| Great Point Partners Iii, Lp | Private Equity Fund | $291M | $1.0M | 109 |
| Great Point Partners Ii, Lp | Private Equity Fund | $65.8M | $1.0M | 103 |
| Great Point Partners Iii A, L.P. | Private Equity Fund | $51.3M | $1.0M | 24 |
| Gpp Iii Pcm, Llc | Private Equity Fund | $31.3M | $100K | 32 |
| Gpp Cf I, Lp | Private Equity Fund | $29.6M | $100K | 62 |
| Gpp Iii Ephicacy, Llc | Private Equity Fund | $20.8M | $100K | 25 |
| Great Point Partners Ii A, Lp | Private Equity Fund | $20.1M | $1.0M | 16 |
| Gpp Iii Axiom, Llc | Private Equity Fund | $14.7M | $250K | 22 |
| Gpp Iii Mlm, Llc | Private Equity Fund | $5.3M | $250K | 24 |
| Gpp Iv Ludi, Llc | Private Equity Fund | $2.7M | $50.0K | 13 |
| Gpp Ii Salmon Co Invest, L.P. | Private Equity Fund | $2.2M | $250K | 19 |
| Gpp Ii Ucs, Llc | Private Equity Fund | $2.2M | $250K | 19 |
| Gpp Iii Ixcells, Llc | Private Equity Fund | $1.6M | $10.0K | 3 |
| Gpp Ii Mdrs Holdings, Llc | Private Equity Fund | $554K | $250K | 4 |
| Gpp Iii Tergus, Llc | Private Equity Fund | $538K | $40.0K | 7 |
| Gpp Iii Bionova, Llc | Private Equity Fund | $136K | $250K | 27 |
| Gpp Ii Offshore Feeder, L.P. | Private Equity Fund | $0 | $1.0M | 2 |
From Form ADV Section 7.B private fund reporting.
Documents (1 archived)
| Form | Period | Size | |
|---|---|---|---|
| Form ADV (full filing) | 03/31/2026 | 4.13 MB | View · PDF · Source ↗ |
Archived copies of the firm's regulatory filings, versioned by content hash.
Disciplinary disclosures
Allegations: GREAT POINT PARTNERS, LLC RECEIVED A REQUEST FOR INFORMATION FROM THE SEC IN APRIL 2014 RELATING TO COMPLIANCE WITH RULE 105 OF REGULATION M UNDER THE SECURITIES EXCHANGE ACT OF 1934. ONE INADVERTENT VIOLATION OF RULE 105 IN APRIL 2013 WAS IDENTIFIED. Status: Final Sanction Detail: GREAT POINT PARTNERS, LLC PAID $109,597.13 ON SEPTEMBER 23, 2014 WHICH PAYMENT INCLUDED DISGORGEMENT OF $43,068, PREJUDGMENT INTEREST OF $1,529.13 AND A CIVIL MONETARY PENALTY OF $65,000.00. Summary: THE SEC ENTERED AN ORDER ON SEPTEMBER 16, 2014, ACCEPTING AN OFFER OF SETTLEMENT BY GREAT POINT PARTNERS, LLC. THE FIRM MADE PAYMENTS DUE ON SEPTEMBER 23, 2014. NO CLIENT OF GREAT POINT PARTNERS, LLC BORE ANY PORTION OF SUCH PAYMENTS OR ANY COSTS RESOLVING THIS MATTER.
Disclosure text reproduced verbatim from the firm's own Form ADV filings.
How they charge
- • Percentage of assets under management
- • Performance-based fees
Services
- • Portfolio management for pooled investment vehicles
Custody
Reported custodians
- Goldman Sachs $383M (13% of AUM) Feb 2021
- National Financial Services (Fidelity) $66.3M (2% of AUM) Feb 2021
- Morgan Stanley $34.6M (2% of AUM) Oct 2024
Amounts as reported in ADV Item 5.K.(3) (custodians holding 10%+ of SMA assets).
Firm reports having custody of client funds or securities (Item 9.A).
Source
All data on this page comes from this firm's Form ADV filings, reproduced without modification. Latest filing: Mar 31, 2026.
View current Form ADV (SEC/IAPD) ↗